{Reference Type}: Journal Article
{Title}: Cognitive performance and brain volume among survivors of pediatric hematological malignancies: a case-control study.
{Author}: Osman AM;Ali AM;Sayed HA;Atta H;Ahmed S;Alieldin N;Abdelhamed MA;Saad K;Shibl A;
{Journal}: Clin Transl Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 12
{Factor}: 3.34
{DOI}: 10.1007/s12094-024-03646-7
{Abstract}: <B>BACKGROUND: </B>Cognitive dysfunction may be one of the hazardous late effects among survivors of pediatric hematological malignancies. Our study aimed to explore cognitive performance and assess the global and regional brain volume changes in survivors of hematological malignancies.<BR><B>METHODS: </B>This case-control study was conducted on 68 survivors of hematological malignancies, with a median follow-up period of 2 years (ranging from 1 to 6.2 years). Stanford-Binet Test was used for cognitive assessment. A quantitative volumetric assessment of the brain was done using the NeuroQuant Brain Magnetic Resonance. Age and sex-matched 68 children were selected as a comparison group.<BR><B>RESULTS: </B>Cancer survivors showed significantly lower levels of IQ and their subtests than the control group. Global brain atrophy was observed in the majority of the survivors. Many risk factors significantly affected different IQ subtests, such as radiotherapy (RTH), high cumulative doses of methotrexate (MTX), and prednisone. At the same time, low white matter volume (WMV) was observed with higher cumulative doses of MTX and anthracyclines.<BR><B>CONCLUSIONS: </B>Hematological malignancies have a negative impact on cognition. Neurocognitive impairment and related brain changes were evident in those who received RTH, HDMTX, or high cumulative doses of steroids.